Overview
Developer of second-generation AI drug discovery technology.
Funding
Amounts as reported; USD estimates shown only when they matchListed 3 funding records. Latest funding: RMB 100M (Equity), Jul 13, 2026.
2 listed records lack a clear date or positive USD estimate for the chart.
| Date | Amount | Investors | Sources |
|---|---|---|---|
| Sep 14, 2026 | Undisclosed · Equity | Monolith VC II SPV Limited, 上海创新工场智创创业投资合伙企业（有限合伙）, 上海奥创先导创业投资合伙企业（有限合伙）, 上海未来涌现企业咨询合伙企业（有限合伙）, 上海燕缘镜春创业投资合伙企业（有限合伙） | No source link |
Evidence Yuanshi Technology completes equity financingOn 2026-09-14, according to Xiniu Data, Yuanshi Technology completed equity financing for an undisclosed amount. Investors were Monolith VC II SPV Limited, Shanghai Innovation Gongchangzhichuang Venture Capital Partnership (Limited Partnership), Shanghai Aochuangxiandao Venture Capital Partnership (Limited Partnership), Shanghai Weilaiyongxianqiye Consulting Partnership (Limited Partnership), Shanghai Yanyuanjingchun Venture Capital Partnership (Limited Partnership). The company is a developer of second-generation AI drug discovery technology. Translated source brief, not a quotation. Check the original before citing. Sources · 0
Monolith VC II SPV Limited, 上海创新工场智创创业投资合伙企业（有限合伙）, 上海奥创先导创业投资合伙企业（有限合伙）, 上海未来涌现企业咨询合伙企业（有限合伙）, 上海燕缘镜春创业投资合伙企业（有限合伙） | |||
| Jul 13, 2026 | RMB 100M ≈ $14.3M · Equity | No source link | |
Evidence Yuanshi Technology raises RMB 100 million in equity financingOn 2026-07-13, according to Xiniu Data, Yuanshi Technology completed equity financing, raising RMB 100 million. The company develops second-generation AI drug discovery technology. Translated source brief, not a quotation. Check the original before citing. Sources · 0
| |||
| Jun 1, 2026 | Tens of millions of RMB · Angel | No source link | |
Evidence Yuanshi Technology raises tens of millions of RMB in angel financingOn 2026-06-01, according to Xiniu Data, Yuanshi Technology completed angel financing, raising tens of millions of RMB. The company is a developer of second-generation AI drug discovery technology. Translated source brief, not a quotation. Check the original before citing. Sources · 0
| |||
Select ▸ on a row to see its source brief and links.
Valuation
Amounts as reported; USD estimates shown only when they matchListed 3 valuation records.
No chartable valuation estimates yet.
3 listed records lack a clear date or positive USD estimate for the chart.
| Date | Amount | Investors | Sources |
|---|---|---|---|
| Sep 14, 2026 | — · Equity | Monolith VC II SPV Limited, 上海创新工场智创创业投资合伙企业（有限合伙）, 上海奥创先导创业投资合伙企业（有限合伙）, 上海未来涌现企业咨询合伙企业（有限合伙）, 上海燕缘镜春创业投资合伙企业（有限合伙） | No source link |
Evidence Yuanshi Technology completes equity financingOn 2026-09-14, according to Xiniu Data, Yuanshi Technology completed equity financing for an undisclosed amount. Investors were Monolith VC II SPV Limited, Shanghai Innovation Gongchangzhichuang Venture Capital Partnership (Limited Partnership), Shanghai Aochuangxiandao Venture Capital Partnership (Limited Partnership), Shanghai Weilaiyongxianqiye Consulting Partnership (Limited Partnership), Shanghai Yanyuanjingchun Venture Capital Partnership (Limited Partnership). The company is a developer of second-generation AI drug discovery technology. Translated source brief, not a quotation. Check the original before citing. Sources · 0
Monolith VC II SPV Limited, 上海创新工场智创创业投资合伙企业（有限合伙）, 上海奥创先导创业投资合伙企业（有限合伙）, 上海未来涌现企业咨询合伙企业（有限合伙）, 上海燕缘镜春创业投资合伙企业（有限合伙） | |||
| Jul 13, 2026 | — · Equity | No source link | |
Evidence Yuanshi Technology raises RMB 100 million in equity financingOn 2026-07-13, according to Xiniu Data, Yuanshi Technology completed equity financing, raising RMB 100 million. The company develops second-generation AI drug discovery technology. Translated source brief, not a quotation. Check the original before citing. Sources · 0
| |||
| Jun 1, 2026 | — · Angel | No source link | |
Evidence Yuanshi Technology raises tens of millions of RMB in angel financingOn 2026-06-01, according to Xiniu Data, Yuanshi Technology completed angel financing, raising tens of millions of RMB. The company is a developer of second-generation AI drug discovery technology. Translated source brief, not a quotation. Check the original before citing. Sources · 0
| |||
Select ▸ on a row to see its source brief and links.
Revenue
Amounts as reported; USD estimates shown only when they matchNo revenue records are listed yet.
No revenue rows to list.
Team, products & investors
Explore
Sources · 0Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
No source links are available for this profile.
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
第二代人工智能制药技术研发商